Reddit Posts
What's a stock you feel like you have to check on every day?
Some Context relative to the China Tariff Negotiations. This will resolve and it is not as dire as it has been made out to be .
$BIVI--Up on Big Volume- $DATS-- Filled the Gap-- $RCAT--Reversal Over 200 DMA Three Stocks Hitting the Scans
BIVI +35% today waiting results on Alzheimer phase 3 in coming days
BIVI it has the potential to explode hard next week if the results are good
BIVI it has the potential to explode hard next week if the results are good
BIVI options are wild right now
The Biotech Train is leaving the Station. All Aboard!: $LUMO, $BIVI, $GOSS
The price of Avalo Therapeutics (AVTX) rose 69% on Wednesday. Why is that so?
BIVI stock gains after trial data for ascites candidate (NASDAQ:BIVI)
💰💰💰Good morning! #premarket #watchlist 09/7 $IMRA -Entry into a Material Definitive Agreement, $BIVI -announces positive results from Phase 2 trial of Alzheimer's treatment, $BPTS -Announces Very Promising Top Line Results of its Phase 2-3 COVA Clinical Study in COVID-19-Related
💰💰💰Good morning! #premarket #watchlist 09/7 $IMRA -Entry into a Material Definitive Agreement, $BIVI -announces positive results from Phase 2 trial of Alzheimer's treatment, $BPTS -Announces Very Promising Top Line Results of its Phase 2-3 COVA Clinical Study in COVID-19-Related
💰💰💰Good morning! #premarket #watchlist 09/7 $IMRA -Entry into a Material Definitive Agreement, $BIVI -announces positive results from Phase 2 trial of Alzheimer's treatment, $BPTS -Announces Very Promising Top Line Results of its Phase 2-3 COVA Clinical Study in COVID-19-Related
Mentions
Premarket Watchlist: **$INDO** & **$EONR** & **$TPET** **$TMDE** & **$RBNE** & **$NAT** **$PRZO** Week Ahead: **$AZTR** : Mar-2/3 Catalyst: https://finviz.com/news/315522/azitra-inc-to-present-at-bio-investment-growth-summit **$BCDA** : Mar-2 PH3 presentation : https://www.globenewswire.com/news-release/2026/2/3/3231040/0/en/BioCardia-Announces-Late-Breaking-Echocardiography-Results-from-the-CardiAMP-HF-Trial-to-be-Presented-at-Technology-and-Heart-Failure-Therapeutics-THT.html **$BIVI** : Mar-4 webinar presentation: https://finviz.com/news/318436/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-march-4
Weekly outlook as of right now : Watchlist Tuesday : **$OLB** **$KXIN** **$SRXH** **$SGN** **$GNS** Week ahead : **$BIVI** : ( Feb-18) : https://finviz.com/news/308857/biovie-announces-abstracts-accepted-for-presentation-at-the-2026-american-college-of-psychiatrists-annual-meeting **$AZTR** : Special meeting (Mar-6) : https://finviz.com/news/303289/azitra-announces-adjournment-of-special-meeting-and-information-for-reconvened-special-meeting **$INTS** : (RS 1-25 Feb-18) : https://finviz.com/news/310352/intensity-therapeutics-announces-reverse-stock-split
I am going for BIVI, increasing volume while price is rather flat, this could signal big money coming in. Sure is a risky move but the last lot of buyers are trapped at the $10 mark, which could mean a 5x return if it plays out.
Copilot gave me BIVI....probably gonna lose my ass on this one.
Sorry, we are in such different worlds on almost everything you said. I don’t invest in a company to dabble. I do my diligence and then I make a significant investment. I don’t invest in biotech stocks to mitigate losses. Risk management is what my index funds are for. I certainly don’t do that in extremely binary companies like this - where the stock goes crazy or goes to zero. My question is a due diligence question. What makes this company so much more compelling than a BIVI or SAVA or ANVS or a whole list of others that have failed despite tantalizing data in early-to-mid stage companies? And as I look more carefully at the data now, what makes us think the effect will be durable? The DLB actually looks very good - but is it durable? However, as I do my due diligence, honestly just on the DLB data this company is wildly under-valued. It’s a shame they are pushing Alzheimer’s ahead of that, where the data is less convincing.
What about BIVI ? They are also working with long covid. Government contract.
Well then, ask Apple why they are relocating manufacturing to India . Secondly, research our existing trade relationships with BIVI and then learn what products they offer before waxing eloquent out of ignorance. You spoke first without reading, and now you are speaking without researching. Good luck on this journey of the thing we call life. clearly, you depend on luck to get through. later Dunning Kruger...
Will BIVI go up ever?!?! $50??
Why you think BIVI gonna bounce soon
I say full port ACHR and then roll the gains into BIVI long
ACHR for short tearm Long tearm, BIVI-(could run to $30)
$BIVI is my favorite biotech play as how low of the float it's. 2x potential.
$BIVI low float @$8🎯 🍌🍑💹
Gotta love low float like $BIVI
$BIVI my low float play 🍌💹
$BIVI my low float play
I I wonder if BIVI can be $100 in 2025 again 😆
Sure thing: ALGS: > Aligos Therapeutics, Inc. (ALGS) is currently trading at $19, showing a strong upward momentum with the RSI indicating overbought conditions across multiple timeframes, suggesting potential for a pullback. The MACD histogram is positive, reinforcing bullish sentiment, while the stock's recent surge above its 10-day SMA of $15.81 and 20-day EMA of $13.90 highlights strong buying pressure. Despite the lack of recent news or significant market interest, the technical indicators suggest a continuation of the uptrend, albeit with caution due to overbought signals. Given the broader market's cautious optimism, ALGS may experience moderate volatility. For today's session, consider a LONG position with an entry around $18.50, targeting $21.00 as the first price target and $23.00 as the second, with a stop loss at $17.00. Confidence in reaching the first target is moderate due to current momentum, while the second target carries lower confidence given potential resistance and market uncertainties. Keep an eye on broader market movements and any emerging news that could impact sentiment. MBLY: > Mobileye Global Inc. (MBLY) is showing signs of short-term bullish momentum, supported by a positive MACD histogram and RSI levels above 60, indicating potential upward movement. The stock's current price of $16.90 is above its 10-day SMA of $16.33, suggesting recent strength, while the broader market sentiment is cautiously optimistic, with technology sectors showing resilience. Recent partnerships and speculation about growth prospects in the autonomous driving sector add to the positive sentiment, although competition remains a concern. Given the high short interest, a short squeeze could further propel the stock upwards. For today's trading session, consider a long position with an entry around $16.80, targeting $17.20 as the first price target and $17.50 as the second, with a stop loss at $16.40 to manage risk. Confidence in reaching the first target is moderate due to mixed market signals, but the second target carries lower confidence given potential resistance and broader market uncertainties. Keep an eye on upcoming announcements and market conditions for any shifts in sentiment. CLDI > Calidi Biotherapeutics, Inc. (CLDI) is currently trading at $2.40, showing a strong upward momentum following its recent public offering priced at $1.69 per share, which raised $7.5 million for operational and R&D purposes. The stock's technical indicators are bullish, with the 10-day SMA at $2.08 and the 8-day EMA at $2.18, suggesting continued upward pressure. The RSI values around 60 indicate moderate buying strength without being overbought, while the MACD histogram supports a positive trend. Despite the lack of significant market sentiment or news, the successful capital raise and potential for future growth could attract investor interest. Given the broader market's cautious optimism, CLDI may experience moderate volatility but with an upward bias. For today's session, consider a long position with an entry around $2.35, targeting $2.60 as the first price target and $2.75 as the second, with a stop loss at $2.20. Confidence in reaching the first target is moderate due to recent positive developments, while the second target carries lower confidence given potential market fluctuations. BIVI: > BioVie Inc. (BIVI) is currently trading at $3.51, showing a strong upward momentum with the 10-day SMA at $3.08 and the 8-day EMA at $3.22, indicating a bullish trend. The RSI values are high, suggesting the stock is overbought, but the MACD histogram remains positive, supporting continued upward movement. Recent trading volumes have been significant, surpassing the 65-day average, which could indicate sustained interest despite the lack of specific news catalysts. Broader market sentiment is cautiously optimistic, with SPY and QQQ showing resilience, which may support BIVI's upward trajectory. Given these factors, a long position is recommended with an entry around $3.50, targeting $3.75 as the first price target and $4.00 as the second, with a stop loss at $3.30 to manage downside risk. Confidence in reaching the first target is moderate due to current momentum, while the second target carries lower confidence given potential resistance and broader market uncertainties. Investors should remain vigilant for any sudden changes in market conditions or unexpected news that could impact BIVI's performance. NXL: > Nexalin Technology, Inc. (NXL) is currently trading at $3.97 with a market cap of approximately $49.9 million and no significant news driving its movement. The stock has shown a strong upward trend recently, with the 10-day SMA at $3.73 and the 20-day EMA at $3.12, indicating bullish momentum. The RSI values are above 60, suggesting the stock is not yet overbought but is approaching that territory. The MACD histogram is positive, reinforcing the bullish sentiment. Given the broader market's cautious optimism and NXL's technical indicators, a long position could be considered. For today's session, an entry price around $3.95 is advisable, with a first target of $4.10 and a second target of $4.25, while setting a stop loss at $3.80 to manage risk. Confidence in reaching the first target is moderate due to the lack of volume and market interest, while the second target carries lower confidence unless new catalysts emerge.
BIVI CLDI ALGS take your pick
Will BIVI hiring $100 in 225?
$BIVI CEO said yes when asked about working on another new drug. 🎯$5 💹🚀
Will BIVI hit $100 anytime soon?? Need professional regard opinion
Sure thing: GNPX: Genprex, Inc. (GNPX) is showing strong bullish momentum with a current price of $2.47, significantly above its 30-day SMA of $0.84, indicating a robust upward trend. The MACD histogram is positive, suggesting continued buying pressure, while the RSI at 64 indicates the stock is nearing overbought territory but still has room for growth. Recent high trading volumes, peaking at over 10 million shares, reflect heightened investor interest, likely driven by speculative activity or anticipation of positive news. Given the broader market's cautious optimism and GNPX's technical indicators, a long position could be favorable today. Consider entering around $2.45, with a first target of $2.70 and a second target of $3.00, setting a stop loss at $2.30 to manage risk. Confidence in reaching the first target is high due to strong momentum, while the second target carries moderate confidence given potential resistance near $3.00. Keep an eye on any emerging news that could impact sentiment, as this stock may not always align with broader market trends. ALLK: Allakos Inc. (ALLK) is currently trading at $1.27, showing a strong upward momentum with recent technical indicators suggesting a bullish trend. The 14-day RSI is at 66, indicating potential overbought conditions but still room for growth, while the MACD histogram is positive, supporting further upside. The stock has seen significant volume spikes in the past month, notably on days with high volatility, suggesting increased investor interest. With the broader market showing cautious optimism, ALLK could benefit from this sentiment, especially given its recent price consolidation and breakout above key moving averages. For today's session, consider entering around $1.25, targeting $1.35 as the first price target and $1.45 as the second, with a stop loss at $1.15 to manage downside risk. Confidence in reaching the first target is high due to strong technical support, while the second target carries moderate confidence given potential resistance levels. Keep an eye on any emerging news that could impact the stock's trajectory. BIVI: BioVie, Inc. (BIVI) is currently trading at $2.59, with technical indicators suggesting a potential bullish momentum. The 8-day EMA at $2.53 and the MACD histogram showing positive divergence indicate upward pressure. The RSI values are neutral, suggesting room for further gains without being overbought. Recent high volume spikes suggest increased investor interest, possibly due to speculative activity or upcoming news. Given the broader market's cautious optimism, BIVI could benefit from any positive sector-specific developments. For today's session, consider entering around $2.60, with a first target of $2.75 and a second target of $2.90. Set a stop loss at $2.45 to manage downside risk. Confidence in reaching the first target is moderate, given the technical setup, while the second target carries lower confidence due to potential resistance and market volatility. HCTI: Healthcare Triangle, Inc. (HCTI) is experiencing significant upward momentum, with the current price at $1.25, well above its 30-day SMA of $0.51, indicating strong bullish sentiment. The RSI values are in overbought territory, suggesting potential for a pullback, but the MACD histogram remains positive, supporting continued upward movement. Recent trading volumes have surged, reflecting increased investor interest, although today's volume data is missing. Given the broader market's cautious optimism and HCTI's recent price action, a long position could be considered. Enter around $1.20, targeting $1.40 as the first price target and $1.50 as the second, with a stop loss at $1.10 to manage downside risk. Confidence in reaching the first target is high due to strong technical indicators, while the second target carries moderate confidence given potential resistance and market volatility. Keep an eye on any emerging news that could impact sentiment or introduce unexpected volatility. ARBB: ARB IOT Group Limited (ARBB) is showing promising momentum with a current price of $0.5545, supported by strong technical indicators. The 10-day SMA at $0.4298 and the 8-day EMA at $0.4869 suggest a bullish trend, while the RSI values above 63 indicate potential overbought conditions but still room for upward movement. The MACD histogram is positive, reinforcing bullish sentiment. Despite the lack of recent news, the stock's recent volume spikes and price action suggest increased investor interest. Given the broader market's cautious optimism, ARBB could benefit from tech sector strength. For today's session, consider entering around $0.55, targeting $0.60 as the first target and $0.65 as the second, with a stop loss at $0.52. Confidence in reaching the first target is high due to technical support, while the second target carries moderate confidence given potential resistance and market volatility.
What will happen with BIVI today?
Can you elaborate the BIVI thing? You bought at what price and why? (had any news/info/feeling)
So what is this BIVI stock?! I bought 100 shares at $4 this morning
Hehe, feel like it halted a bit, ended up going BIVI for now
BIVI rocketing ⚠️⚠️💹💹
BIVI rocketing ⚠️⚠️💹💹
BIVI looks like about to do DRUG moves. Shorts were still trapped. High borrowing rate and low float. Holding above vwap really well and ready to launch.
BIVI looks like about to do DRUG moves. Great potential
BIVI looks like about to do DRUG moves
Just took a position on BIVI @ $2.90
Premarket mover BIVI. Keep an eye out for a rebound gap filling to the upside. Could be the runner of the day.
Eyes on BIVI as it might gap filling to the upside. Could be the runner of the day.
Yep, I’m hoping for a $DRUG to bounce back and $BIVI BIVI is ripping up now
I'm watching BIVI premarket tomorrow. Could see a bounce to $5.
BIVI, low float. Could bounce premarket
BIVI, low float. Could bounce premarket
BIVI, offer was done. Might gap up again in the morning.
BIVI at a discount
BIVI less than 2M shares actual float today. Expecting some crazy moves.
Anyone else looking at BIVI?
BIVI, trading above VWAP on drug approval news in Japan.
The fuk is happening with the stonk BIVI. Up by 160%. 
Buy BIVI Monday morning and retire. Sure it popped 95% on Friday but it’s now got a clear shot at $100M market cap which would be around $12/share….its currently under $3. So yea, that. Hot money from companies like DRUG will easily come pouring in.
Wow what a month for BIVI. thoughts on a rise back to $10 tho
BIVI$ is going to skyrocket next week
BIVI is the next DRUG. You heard it here first.
put a lil in AMLX and BIVI lottos.... ready to wake up Monday in a new Bugatti
What do ya'll think about BIVI?
BIVI hitting $3 on Monday load up
BIVI gonna be the next DRUG
BIVI is the most regarded and lucky trade i've ever been in... and I have no clue why its pumping 
BIVI update and article: [BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID](https://feeds.issuerdirect.com/news-release.html?newsid=5378699977249880)
It looks like BIVI is voting on a reverse split in July. I'm not sure if that matters for the short term though. Also I saw an advertisement promoting the stock on the news this AM forget which network. So I did some poking at it. Price action got strange right after the ad ran...
I lost $700 on BIVI.. no chicken dinner for me :(
Does anyone have any useful information on BIVI? I know why it dropped and all that, but does any long term investor in it have any idea what the future may look like for it?
I'm up 72% overall on it since I got in. I went in on Biovie just before this and lost a good chunk. BETS helped me recover my loss from BIVI. I NEED A WIN. WE NEED A WIN 🏆 🙏
So options are valued based on a ton of stuff (look up greeks, delta, gamma, theta), but one of which is how volatile the stock is. How slow or how fast it changes. The more volatile a stock, the more valuable the option. Volatility example: You and I buy an apple (AAPL) call option today. We paid $1. The underlying stock is currently at $190. You sold your option for $3 when apple went to $195. Congrats you made $2 profit! I hold, lucky for me apple went to $1000. But I am greedy and don't sell. I go to sleep and wake up. AAPL is back at $195, wtf? I get upset but its ok I'll just sell my option (the same one we bought yesterday) for $500 (500% profit). This is because the option is now considered more valuable due to its volatility. Buyers of this option understand that there is a chance it could go back to $1000, so they are willing to pay more for this potential. Volatility can be seen in the form of earning calls, world disasters (covid, war, banks failing), pharmaceutical trials (check out BIVI, options were priced through the roof because they were about to announce test results of their alzheimer's drug), ceos getting fired (open ai fires CEO and tanked microsoft stock price), a lot of random other crap
CABA for sure Or BIVI Or SEEL Or any biotech stock that recently took a massive dive but will be recovering.
BIVI had bad news on one of their clinical trials. And now the tax loss selling begins...
Hey, let's say the premiums are put-solutely a great deal, as BIVI skyrockets to the moon with our newfound knowledge of stocks and options!
Sometimes this is the smartest move, sometimes the dumbest. If you like the fundamentals, no reason not to buy cheap. But if a price move indicates a change in fundamentals, best to stay out. Don’t know anything about BIVI personally so I can’t say
BIVI train had a head on collision 💥 😳
rip BIVI. Got out at 5.02 yesterday so worked out for me but WOW what a pump and dump. Might buy in for future moonshot if it bottoms out.
At least when you are selling naked puts you have a defined risk. When you short the 15Dec23 2.5 puts and BIVI lands at 1 you've lost 1.00. At 2.00 you've broken even. If Alzheimer's is not there only product it's not a terrible idea.
Binary event for their Alzheimer’s Phase 3 data. It’s most likely going to fail and be under $1. Don’t be trapped by this. Look at my comment history when someone made a similar post about DRRX puts. I said the premiums were juiced because it’s going to crash. It crashed 80%. There’s a tiny tiny chance data is good and the stock goes to $10+, but the odds are against BIVI. Don’t mess around with biotech binary events IMO unless it’s your speciality
Risk. This is a low priced and low volume biopharm stock that has been losing money with low analyst ratings. I'm admittedly a very conservative trader, so wouldn't trade BIVI even with your money . . .
Yolo on BIVI. This is financial advice.
I got diomand balls for TCBP...I would say BIVI is on the up...lots of good groundwork for Biovie and lots of anticipation to the upside. Maybe check them out.
Check BIVI ... Alzheimer results phase 3 in coming days
Check BIVI ... Alzheimer results phase 3 in coming days
Been scaling into $BIVI heavily. Props to whoever called it out earlier. Looks like it's ready for higher moves too.
Whenever told me to invest in BIVI, I love you. I didn’t trust you and only invested 900, but I’ve already doubled it so thank you. Hope someone is getting rich off it
I got out to early. Won’t make the same mistake with TCBP or BIVI